The effects of a magnetic IronQ complex on endothelial progenitor cells expansion in vitro
Article Sidebar
Main Article Content
Abstract
Introduction: In vitro proliferation and expansion of endothelial progenitor cells play important roles in the cell-based therapies for patient with acute myocardial infarction or ischemic heart disease.
Objective: To determine the effect of magnetic IronQ complex on the proliferation of endothelial progenitor cells in vitro.
Methods: Peripheral blood mononuclear cells from venous blood was isolated by Ficoll-Hypaque gradient centrifugation method. PBMCs (1x106 cell/4-mL) were cultured with various concentrations of IronQ at 0, 100, 200, 300, 400 and 500 μg/mL for 17 days. Cell morphology was observed and recorded under inverted microscope. Specific marker for endothelial progenitor cells was characterized by immunostaining with CD34-FITC and analyzed by flow cytometer.
Results: Under inverted microscope, after 7 days of incubation, PBMCs showed stem cell-typical morphology surrounded by spindle-shaped cells. Interestingly, in the presence of IronQ, those colony-forming cells were increased in dose and time dependent manner. It was observed that only the cell incubated with IronQ was promoted spindle-shaped cells to form tube-like structure similar to the process of vasculogenesis. Cell incubated with IronQ for 10 days was positive with CD34 in dose dependent manner. Cells in the presence of IronQ at 500 μg/mL was strongly positive compared to others concentrations with the value of 47.66±2.52%. This indicated the increasing of endothelial progenitor cell proliferation.
Conclusion: This is the first study demonstrated the using of IronQ to promote endothelial progenitor cell proliferation in vitro without addition of any growth factors or specific growth activator leading to the cost reduction and also able to increase efficiency for cell-based therapy.
Bull Chiang Mai Assoc Med Sci 2016; 49(1): 106-113. Doi: 10.14456/jams.2016.3
Article Details
Personal views expressed by the contributors in their articles are not necessarily those of the Journal of Associated Medical Sciences, Faculty of Associated Medical Sciences, Chiang Mai University.
References
2. Takayuki A, Haruchika M, Tomono T, Christoph K, Christopher P, Marcy S, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85: 221-8.
3. Bartunek J, Vanderheyden M, Vandekerckhove B, Mansour S, De Bruyne B, De Bondt P, et al. Intracoronary injection of CD133-positive enrich bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety. Circulation 2005; 112: 1178-83.
4. Ben-Shoshan J, George J. Endothelial progenitor cells as therapeutic vectors in cardiovascular disorders: From experimental models to human trials. Pharmacol Ther 2007; 115: 25-36.
5. Yeh ET, Zhang S, Wu HD, Korbling M, Willerson JT, Estrov Z. Transdifferentiation of human peripheral blood CD34+- enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo. Circulation 2003; 108: 2070-3.
6. Rouhl RP, van Oostenbrugge RJ, Damoiseaux J, Cohen JW, Lodder J. Endothelial progenitor cell research in stroke: a potential shift in pathophysiological and therapeutical concepts. Stroke 2008; 39: 2158-2165.
7. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: E1-E7.
8. Tepper OM, Galiano RD, Capla JM. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002; 106: 2781-6.
9. Fadini GP, de Kreutzenberg SV, Coracina A, Baesso I, Agostini C, Tiengo A, et al. Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk. Eur Heart J 2006; 27: 2247-55.
10. Ferrari N, Glod J, Lee J, Kobiler D, Fine HA. Bone marrow-derived, endothelial progenitor-like cells as angiogenesis-selective gene-targeting vectors. Gene Ther 2003; 10: 647–56.
11. Debatin KM, Wei J, Beltinger C. Endothelial progenitor cells for cancer gene therapy. Gene Ther 2008; 15: 780–6.
12. Carlos BB, Susana N, Macarena LF, Daniel PC, Magda H, Juan S, et al. An affordable method to obtain cultured endothelial cells from peripheral blood. J Cell Mol Med 2013; 17(11): 1475-83.
13. Jianguo W, Tianhang L, Hong Z, Zhengmao L, Jianwei B, Xuchao X, et al. Optimization of culture conditions for endothelial progenitor cells from porcine bone marrow in vitro. Cell Prolif 2010; 43: 418-26.
14. Narin Tuntamong. A study of the relaxivity of Iron-based complexes [Term paper]. Faculty of Associated Medical Sciences: Chiang Mai University; 2013 (in Thai).
15. Risau W, Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol 1995; 11: 73-91.
16. Barber CL, Iruela-Arispe ML. The ever-elusive endothelial progenitor cell: identities, functions and clinical implications. Pediatr Res 2006; 59: 26R–32R.
17. Zhao LR, Du YJ, Chen L, Liu ZG, Pan YH, Liu JF, et al. Quercetin protects against high glucose-induced damage in bone marrow-derived endothelial progenitor cells. Int J Mol Med 2014; 34(4):1025-1031.
18. Ito H, Rovira II, Bloom ML, Takeda K, Ferrans VJ, Quyyumi AA, et al. Endothelial progenitor cells as putative targets for angiostatin. Cancer Res 1999; 59: 5875-5877.
19. Hamed S, Alshiek J, Aharon A, Brenner B, Roguin A. Red wine consumption improves in vitro migration of endothelial progenitor cells in young, healthy individuals. Am J Clin Nutr 2010; 92: 161-9.
20. Pourcelot E, Lenon M, Mobilia N, Cahn JY, Arnaud J, Fanchon E, et al. Iron for proliferation of cell lines and hematopoietic progenitors: Nailing down the intracellular function iron concentration. Biochim Biophys Acta 2015; 1853: 1596-605.